WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 300220
CAS#: 97657-92-6 (HCl)
Description: Latrepirdine, also known as dimebolin (sold as Dimebon), is an antihistamine drug which has been used clinically in Russia since 1983. Research is continuing in both Russia and western nations into potential applications as a neuroprotective drug to combat Alzheimer's disease and, possibly, as a nootropic as well. However, a Phase III clinical trial for Alzheimer's disease treatment failed to show any benefit. (Source: http://en.wikipedia.org/wiki/Latrepirdine)
MedKoo Cat#: 300220
Name: Latrepirdine HCl
CAS#: 97657-92-6 (HCl)
Chemical Formula: C21H26ClN3
Exact Mass: 355.18153
Molecular Weight: 355.9
Elemental Analysis: C, 70.87; H, 7.36; Cl, 9.96; N, 11.81
Latrepirdine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Latrepirdine dimebolin Dimebon
IUPAC/Chemical Name: 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride
InChi Key: WGQCGOMSKOHLMD-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H25N3.ClH/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17;/h4-7,12-13H,8-11,14H2,1-3H3;1H
SMILES Code: CC1=CC=C(CCN2C3=C(CN(C)CC3)C4=C2C=CC(C)=C4)C=N1.[H]Cl
The following data is based on the product molecular weight 355.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Vignisse J, Steinbusch HW, Bolkunov A, Nunes J, Santos AI, Grandfils C, Bachurin S, Strekalova T. Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 14. [Epub ahead of print] PubMed PMID: 21163318.
2: Bachurin SO, Ustyugov AA, Peters O, Shelkovnikova TA, Buchman VL, Ninkina NN. Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds. Dokl Biochem Biophys. 2009 Sep-Oct;428:235-8. PubMed PMID: 20848907.
3: Tabira T. [Development of new drugs for Alzheimer's disease]. Brain Nerve. 2010 Jul;62(7):787-96. Review. Japanese. PubMed PMID: 20675883.
4: Shoji M. [Drug therapy for Alzheimer's disease]. Brain Nerve. 2010 Jul;62(7):777-85. Review. Japanese. PubMed PMID: 20675882.
5: Learning from failure. Nat Rev Drug Discov. 2010 Jul;9(7):499. PubMed PMID: 20614555.
6: Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis. 2010;21(2):389-402. PubMed PMID: 20555134.
7: Sachdeva D, Burns A. Dimebolin in Dementia. CNS Neurosci Ther. 2010 Jun 11. [Epub ahead of print] PubMed PMID: 20553307.
8: Mechanism matters. Nat Med. 2010 Apr;16(4):347. PubMed PMID: 20376007.
9: Gao M, Wang M, Hutchins GD, Zheng QH. [(11)C]Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2529-32. Epub 2010 Mar 3. PubMed PMID: 20299213.
10: Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science. 2010 Mar 12;327(5971):1309. PubMed PMID: 20223954.